Understanding Next-Generation Immune Checkpoints and Deciphering Key Roles in the TME

Catherine Sabatos-Peyton, PhD is the Executive Director, Head of Immune Modulation, Exploratory Immuno-oncology, Novartis Institutes for BioMedical Research. During her PhD at Harvard University, Catherine was part of the team that first described TIM-3, now understood as a critical immune and leukemic stem cell modulator in AML and MDS. Dr Sabatos-Peyton went on to a postdoctoral fellowship at UCSF, followed by a fellowship at the University of Bristol in the UK. Dr Sabatos-Peyton was Director of Immunology at CoStim Pharmaceuticals, developing therapeutic antibodies against checkpoint proteins for cancer treatment until its acquisition by Novartis in February 2014. Dr Sabatos-Peyton has continued there, now as Head of Immune Modulation, bringing cancer therapeutic treatments to the clinic with a focus on preclinical research to establish novel therapies to overcome the suppressive tumor microenvironment.